Zai Lab Limited ADR(ZLAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:16 AM ET (Korea 10/29 17:16)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.7 | Insider Own | 7.07% | Shs Outstand | 112.2M | Perf Week | -4.79% |
| Market Cap | 2.60B | Forward P/E | - | EPS next Y | 3.4% | Insider Trans | -3.11% | Shs Float | 104.8M | Perf Month | -11.15% |
| Enterprise Value | 2.14B | PEG | - | EPS next Q | -0.56 | Inst Own | 35.82% | Short Float | 8.44% | Perf Quarter | 26.52% |
| Income | -0.19B | P/S | 5.77 | EPS this Y | -38.94% | Inst Trans | -5.52% | Short Ratio | 8.57 | Perf Half Y | 11.04% |
| Sales | 0.45B | P/B | 4.26 | EPS next 5Y | 3.72% | ROA | -16.86% | Short Interest | 8.84M | Perf YTD | 30.61% |
| Book/sh | 5.41 | P/C | 3.62 | EPS past 3/5Y | 29.68% 14.26% | ROE | -26.98% | 52W High | -16.22% ($27.50) | Perf Year | -9.33% |
| Cash/sh | 6.36 | P/FCF | - | Sales past 3/5Y | 29.03% 56.57% | ROIC | -30.51% | 52W Low | 44.36% ($15.96) | Perf 3Y | -1.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 17% | Gross Margin | 56.47% | Volatility(W/M) | 6.43% 5.05% | Perf 5Y | -78.1% |
| Dividend TTM | - | EV/Sales | 4.74 | Sales Y/Y TTM | 5.13% | Oper. Margin | -58.74% | ATR (14) | 1.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.92 | EPS Q/Q | -21.77% | Profit Margin | -41.86% | RSI (14) | 44.18 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.13 | Sales Q/Q | -3.52% | SMA20 | -4.68% ($24.17) | Beta | 0.75 | Target Price | $33.76 |
| Payout | - | Debt/Eq | 0.42 | Earnings | 2026/11/5 | SMA50 | -8.22% ($25.1) | Rel Volume | 0.68 | Prev Close | $23.58 |
| Employees | 1784 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 26.41% 2.35% | SMA200 | 9.98% ($20.95) | Avg Volume(3M) | 1.03M | Price | $23.04 |
| IPO | 2017/9/20 | Option/Short | Yes/Yes | Trades | 8154 | Volume | 704,068 | Change | -2.29% |
🧬 A China-focused biopharmaceutical company that develops and commercializes innovative new drugs. It combines in-house development with the in-licensing of global new drugs across areas such as oncology, autoimmune diseases, and infectious diseases, targeting both the Chinese and global markets, and holds commercialized products alongside a late-stage clinical pipeline. It has established itself as a Chinese biopharma operator that combines in-licensing of new drugs with in-house development.
Over the past 1 year, roughly in the middle
16% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Next earnings report: November 5
7 days to go.
ZLAB has a sound balance sheet but weak earning power
Of every $100 in sales, $58.74 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -38.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $577. Peers typically go for $1,953.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -78.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #80 of 594 in the industry
Based on market cap of $3B.
FAQ
What kind of company is ZLAB?
ZLAB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ZLAB?
The market cap of ZLAB is approximately $2.6B, ranking 1,865 within its sector.
What is the 52-week high and low for ZLAB?
ZLAB has recorded a 52-week high of $27.50 and a low of $15.96.
